Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
PEMMELA trial: what clinicians have said so far
Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients
- NCT04287829 ↗
- Active, not recruiting
- The Netherlands Cancer Institute
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on PEMMELA (pembrolizumab plus lenvatinib in second-line and third-line malignant pleural mesothelioma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on PEMMELA so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 6 posts on X, typically up to 26 once built | |
| 3 YouTube videos, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- PEMbrolizumab Plus Lenvatinib In Second Line And Third Line Malignant Pleural MEsotheLiomA Patients(PEMMELA)
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Mesotheliomas Pleural
- Interventions
- Pembrolizumab; Lenvatinib
- Arms
- pembrolizumab and lenvatinib · Experimental
- Enrollment
- 58
- Primary outcomes
- Objective response rate defined by Modified RECIST 1.1 criteria for pleural mesothelioma
- Sponsor
- The Netherlands Cancer Institute with Merck Sharp & Dohme LLC
- Start
- Mar 1, 2021
- Primary completion
- Dec 5, 2024 (estimated)
- Results posted
- No
- Registry record
- NCT04287829 · updated Nov 5, 2024
Publications
linked from the registry- Douma LH, van der Noort V, Lalezari F, de Vries JF, Monkhorst K, Smesseim I, Baas P, Schilder B, Vermeulen M, Burgers JA, de Gooijer CJ. Pembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study. Lancet Oncol. 2025 Dec;26(12):1676-1684. doi: 10.1016/S1470-2045(25)00514-5. PubMed 41308680
- Douma LH, Lalezari F, van der Noort V, de Vries JF, Monkhorst K, Smesseim I, Baas P, Schilder B, Vermeulen M, Burgers JA, de Gooijer CJ. Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study. Lancet Oncol. 2023 Nov;24(11):1219-1228. doi: 10.1016/S1470-2045(23)00446-1. Epub 2023 Oct 13. PubMed 37844598